BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29333021)

  • 1. Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
    Agarwal MB; Bhurani D; Shah C; Sood N; Singhal M; Kamat A; Chezhian S; Mishra S; Nagrale D
    Indian J Med Paediatr Oncol; 2017; 38(4):508-515. PubMed ID: 29333021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
    Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
    Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
    Lee CS; Rattu MA; Kim SS
    J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey.
    Göçer M; Kurtoğlu E
    Blood Res; 2020 Dec; 55(4):206-212. PubMed ID: 33303706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
    Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
    Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
    Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA
    Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL.
    Akpinar S; Dogu MH; Celik S; Ekinci O; Hindilerden IY; Dal MS; Davulcu EA; Tekinalp A; Hindilerden F; Ozcan BG; Hacibekiroglu T; Erkurt MA; Bagci M; Namdaroglu S; Korkmaz G; Bilgir O; Cagliyan GA; Ozturk HBA; Serin I; Tiryaki TO; Ozatli D; Korkmaz S; Ulas T; Eser B; Turgut B; Altuntas F
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):169-173. PubMed ID: 34629286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL.
    Dartigeas C; Slama B; Doyle M; Tapprich C; Albrecht C; Dupuis S; Wapenaar R; Schmidt-Hieber C; Leblond V
    Clin Hematol Int; 2022 Sep; 4(3):65-74. PubMed ID: 36103041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ibrutinib: A new drug of B-cell malignancies].
    Thieblemont C
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S85-90. PubMed ID: 26118882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
    Tucker DL; Rule SA
    Ther Clin Risk Manag; 2015; 11():979-90. PubMed ID: 26150724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
    Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.